促甲状腺激素释放激素刺激试验对垂体瘤患者的诊断价值
Diagnostic value of thyrotropin-releasing-hormone stimulation in patients with pituitary tumor.
作者信息
Cook D M, Greer M A, Paxton H
出版信息
West J Med. 1987 Aug;147(2):161-4.
Plasma prolactin response to thyrotropin-releasing-hormone (TRH) stimulation was diminished in 30 patients with prolactinomas and 9 patients with acromegaly who had normal serum prolactin levels. There was no overlap of prolactin responses when compared with 32 control patients. Responses of ten patients with adrenocorticotropin (ACTH)-secreting pituitary tumors were similar to those of controls. Plasma growth hormone concentrations after TRH stimulation changed significantly in 28% of normal control and 20%, 25% and 50% of patients with prolactin-, growth hormone- and ACTH-secreting pituitary tumors, respectively. Our data suggest that the blunted TRH-induced rise in plasma prolactin levels in patients with prolactinomas and those with acromegaly may be related to humoral factor(s) affecting TRH receptor or postreceptor function. Growth hormone responses to TRH are nonspecific and should not be considered a marker for active acromegaly.
30例催乳素瘤患者和9例血清催乳素水平正常的肢端肥大症患者对促甲状腺激素释放激素（TRH）刺激的血浆催乳素反应减弱。与32例对照患者相比，催乳素反应无重叠。10例分泌促肾上腺皮质激素（ACTH）的垂体瘤患者的反应与对照组相似。TRH刺激后，正常对照组28%、催乳素分泌型垂体瘤患者20%、生长激素分泌型垂体瘤患者25%以及促肾上腺皮质激素分泌型垂体瘤患者50%的血浆生长激素浓度发生显著变化。我们的数据表明，催乳素瘤患者和肢端肥大症患者中TRH诱导的血浆催乳素水平升高减弱可能与影响TRH受体或受体后功能的体液因子有关。生长激素对TRH的反应是非特异性的，不应被视为活动性肢端肥大症的标志物。
Zotero 插件